Elixxer (Elixxer) Change In Receivables : $-0.02 Mil (TTM As of Sep. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Elixxer Change In Receivables?

Elixxer's change in receivables for the quarter that ended in Sep. 2023 was $0.00 Mil. It means Elixxer's Accounts Receivable stayed the same from Jun. 2023 to Sep. 2023 .

Elixxer's change in receivables for the fiscal year that ended in Dec. 2022 was $0.08 Mil. It means Elixxer's Accounts Receivable declined by $0.08 Mil from Dec. 2021 to Dec. 2022 .

Elixxer's Accounts Receivable for the quarter that ended in Sep. 2023 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Elixxer's liquidation value for the three months ended in Sep. 2023 was $-8.53 Mil.

Elixxer Change In Receivables Historical Data

The historical data trend for Elixxer's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elixxer Change In Receivables Chart

Elixxer Annual Data

Trend

Jun12

Jun13

Jun14

Jun15

Jun16

Sep17

Sep18

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

-0.10

0.13

0.08

Elixxer Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Change In Receivables	Get a 7-Day Free Trial															-	-0.02	-	-	-

Elixxer Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02 Mil.

Elixxer (OTCPK:ELIXF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Elixxer's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Elixxer's accounts receivable are only considered to be worth 75% of book value:

Elixxer's liquidation value for the quarter that ended in Sep. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.083	-	8.617	+	0.75 * 0	+	0.5 * 0
=	-8.53

Elixxer Change In Receivables Related Terms

Thank you for viewing the detailed overview of Elixxer's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Elixxer (Elixxer) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elixxer Ltd (OTCPK:ELIXF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

1100 Boulevard Rene- Levesque Ouest, Suite 700, Montreal, QC, CAN, H5B 4N4

Website

https://www.elixxer.com

Elixxer Ltd is a Canada-based cannabis investment firm in the legal cannabis market. It invests in cannabis-related businesses that are fully licensed for the cultivation, production, and sale of cannabis and cannabis-derived products.